Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
AbCellera Biologics Inc. (NASDAQ: ABCL)
ABCL Stock Predictions and Ratings
WSX Rating:
HOLD
WSX Forecast (1yr):
3.90%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
32.30%
ABCL Stock Analysis
ABCL
PE Ratio:
ABCL
PEG Ratio:
Not Available
ABCL
Forward EPS Growth (12 month):
0.00%
ABCL
PS Ratio:
22.1
ABCL
PSG Ratio:
1.4
ABCL
Forward Revenue Growth (12 month):
15.80%
ABCL Articles
No data was found